Labcorp’s latest acquisition brings the oncology testing business of BioReference Health. Opko Health, BioReference’s parent, has been cutting costs to return to profitability.
Labcorp is buying the clinical diagnostics and reproductive women’s health businesses of BioReference Health, excluding those assets in New York and New Jersey. Labcorp has returned to being fully focused on lab testing after last year’s spinoff of Fortrea, its former clinical trial services business.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Ngenla, a hormone drug from partners Pfizer and Opko Health, is now FDA approved for treating children with growth hormone deficiency. The once-weekly injectable biologic will compete against an Ascendis Pharma product that won its FDA approval in 2021.
Merck has licensed global rights to an Opko Health vaccine in development for Epstein-Barr virus. The preclinical vaccine candidate, made with technology that displays multiple viral antigens to prompt an immune response, could compete against programs from Moderna and Valneva.
The FDA has rejected Pfizer’s somatrogon, a long-acting form of human growth hormone designed for once-weekly dosing. The setback delays Pfizer and partner Opko Health from competing against a newly approved human growth hormone drug from Ascendis Pharma that is also designed for once-weekly dosing.
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company's goal of translating insights from genomics data and analytics into making precision medicine a standard of care.
Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received.
Frost, formerly Teva's chairman, is alleged in a lawsuit filed Friday to have taken part in a pump-and-dump operation that netted $27 million over five years.
As pharmaceutical companies look for ways to add value to their drugs to solve problems like adherence, many see digital health as an important part of that strategy. Respiratory drug developer Opko Health (NYSE: OPK) has acquired an Israeli medical device startup, Inspiro Medical, with a digital dry powder inhaler under development, according to a […]